Heron Therapeutics (HRTX) Leases (2019 - 2025)
Heron Therapeutics (HRTX) has disclosed Leases for 9 consecutive years, with $708000.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Leases fell 79.59% year-over-year to $708000.0, compared with a TTM value of $708000.0 through Sep 2025, down 79.59%, and an annual FY2024 reading of $2.8 million, down 48.75% over the prior year.
- Leases was $708000.0 for Q3 2025 at Heron Therapeutics, down from $1.4 million in the prior quarter.
- Across five years, Leases topped out at $15.6 million in Q1 2021 and bottomed at $708000.0 in Q3 2025.
- Average Leases over 5 years is $7.0 million, with a median of $6.5 million recorded in 2023.
- The sharpest move saw Leases decreased 14.5% in 2021, then tumbled 79.59% in 2025.
- Year by year, Leases stood at $9.8 million in 2021, then dropped by 22.22% to $7.6 million in 2022, then dropped by 28.87% to $5.4 million in 2023, then tumbled by 48.75% to $2.8 million in 2024, then tumbled by 74.6% to $708000.0 in 2025.
- Business Quant data shows Leases for HRTX at $708000.0 in Q3 2025, $1.4 million in Q2 2025, and $2.1 million in Q1 2025.